Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 61 Novo Nordisk's key diabetes care products remain broadly available in the USA Value market shares of Novo Nordisk key products in the USA Share of unrestricted market access of Novo Nordisk key products in the USA Value market share 80% 60% 40% 20% 0% Aug 2015 Source: IQVIA NSP August 2018; VictozaⓇ TresibaⓇ NovoLogⓇ LevemirⓇ Unrestricted Market access 100% 80% 60% 40% 20% 0% Aug 2018 Jul 2015 Note: Market shares: NovoLogⓇ: share of rapid acting insulin segment; LevemirⓇ: share of basal insulin segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment changing diabetes® VictozaⓇ TresibaⓇ NovoLogⓇ Source: FingerTip Formulary bridge, July 2018 Nomenclature and Xponent PlanTrak; only considers bridged volume; excludes cash and mail order data; Note: Unrestricted access excludes prior authorisation, step edits and other restrictions LevemirⓇ access based on FlexTouch® Pen; NovoLogⓇ access based on FlexPen®; only considers bridged volume; TresibaⓇ launched in January 2016 LevemirⓇ Jul 2018 novo nordisk

View entire presentation